51. Methylation of PLK-1 Potentially Drives Bendamustine Resistance in Leukemia Cells.
- Author
-
Itabashi T, Ueda T, Fukunaga R, Asano T, and Itoh Y
- Subjects
- Humans, Cell Line, Tumor, Decitabine pharmacology, DNA Methylation, Azacitidine pharmacology, Gene Expression, ATP Binding Cassette Transporter, Subfamily B genetics, ATP Binding Cassette Transporter, Subfamily B metabolism, Leukemia genetics, Leukemia drug therapy, Epigenesis, Genetic, Bendamustine Hydrochloride pharmacology, Drug Resistance, Neoplasm genetics, Protein Serine-Threonine Kinases genetics, Protein Serine-Threonine Kinases metabolism, Polo-Like Kinase 1, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins metabolism, Cell Cycle Proteins genetics, Cell Cycle Proteins metabolism
- Abstract
Background: Drug resistance remains a significant impediment in leukemia treatment. While Bendamustine hydrochloride (BH) stands out as a promising therapeutic agent for non-Hodgkin's lymphoma and mantle cell lymphoma, the mechanisms of resistance to BH are not yet fully understood. Our study focuses on elucidating the mechanisms behind bendamustine resistance in leukemia cells, with a specific emphasis on epigenetics., Methods: Bendamustine-resistant cells were cultivated from human B cell lymphoblastic leukemia cell lines through systematic and sustained exposure to bendamustine, using the limiting dilution method. Gene expression was assessed via real-time polymerase chain reaction, while the expression of the multidrug resistance protein 1 (MDR1) was evaluated using flow cytometry., Results: Bendamustine-resistant leukemia cells exhibited a decreased RNA expression level for Polo-like kinase-1 (PLK-1). Notably, after treatment with the demethylating agent 5-aza-2'-deoxycytidine, PLK-1 gene expression surged significantly, enhancing bendamustine's cytotoxicity in the resistant leukemia cells. However, MDR1 expression, as determined by flow cytometry, remained consistent between parental and bendamustine-resistant leukemia cells., Conclusions: Our findings indicate that the methylation of the PLK-1 gene plays a pivotal role in modulating PLK-1 expression and is central to the development of bendamustine resistance in leukemia cells.
- Published
- 2024
- Full Text
- View/download PDF